[News] SSO 2024

A phase 1 trial of short-course pre-operative chemoradiotherapy (CRT) as part of total neoadjuvant therapy in potentially resectable gastric cancer was presented by Brian Badgwell (MD Anderson Cancer Center, Houston, TX, USA). 24 patients received 30 Gy radiation in 10 fractions plus concurrent capecitabine or fluorouracil, followed by chemotherapy for 2 months and then surgery. The primary objective was safety. CRT-related adverse events included grade 3–4 lymphopenia (eight [33%] patients) and grade 3 anaemia (one [4%] patient).